Patent application number | Description | Published |
20120205330 | METHOD AND APPARATUS FOR MARKETING GREETING CARDS IN DISPLAY FIXTURES - A greeting card display includes an upper tier and a lower tier positioned below the upper tier. The upper and lower tiers include multiple rows of pockets for displaying greeting cards. Some of the pockets of the upper tier and the bottom tier, typically the pockets in each of the bottom rows, present greeting cards in a full-facing manner to display all or substantially all of the full face of each greeting card. The upper tier can include a card highlighter, positioned along one of the rows, configured with pockets to present and highlight cards placed therein. Shadowboxes capable of displaying a greeting card in a full-facing manner can be positioned above the upper tier on the display and are designed to attract the attention of the consumer. A display panel, designed to evoke emotions associated with greeting cards in the shadowboxes, can be positioned between one or more of the shadowboxes. | 08-16-2012 |
20130026116 | Greeting Card Display Fixture - A greeting card display includes an upper tier and a lower tier positioned below the upper tier. The upper and lower tiers include multiple rows of pockets for displaying greeting cards. Some of the pockets of the upper tier and/or the bottom tier, typically the pockets of the bottom rows, can present greeting cards in a full-facing manner to display all or substantially all of the full face of each greeting card. The upper tier can include a card highlighter, positioned along one of the rows, configured with pockets to present and highlight cards placed therein. | 01-31-2013 |
20140075794 | Greeting Card Display Fixture - A greeting card display includes an upper tier and a lower tier positioned below the upper tier. The upper and lower tiers include multiple rows of pockets for displaying greeting cards. Some of the pockets of the upper tier and/or the bottom tier, typically the pockets of the bottom rows, can present greeting cards in a full-facing manner to display all or substantially all of the full face of each greeting card. The upper tier can include a card highlighter display, positioned along one of the rows, configured to present and highlight cards placed therein. | 03-20-2014 |
Patent application number | Description | Published |
20100086185 | Image creation, analysis, presentation and localization technology - Image processing, creation and analysis techniques include using computer technology to identify a plurality of structures of interest in an image, such as spinal discs in a medical diagnostic image. Such techniques can also be used to improve image creation through the use of localizers which can help identify portions of an image, and the use of computer programs to combine multiple images into a single image for review. | 04-08-2010 |
20110123078 | Automated Neuroaxis (Brain and Spine) Imaging with Iterative Scan Prescriptions, Analysis, Reconstructions, Labeling, Surface Localization and Guided Intervention - Automated spine localizing, numbering and autoprescription system enhances correct location of diseased or injured tissue, even allow multi-spectral diagnosis. Externally located this tissue is facilitated by an integrated self adhesive spatial reference and skin marking system that is designed for a variety of modalities to include MRI, CT, SPECT, PET, planar nuclear imaging, radiography, XRT, thermography, optical imaging and 3D space tracking. The device ranges from a point localizer to a more multifunctional and complex grid/phantom system. The specially designed spatial reference(s) is affixed to an adhesive strip with corresponding markings so that after applying the unit to the skin/surface and imaging, the reference can be removed leaving the skin appropriately marked. The localizer itself can also directly adhere to the skin after being detached from the underlying strip. A spine autoprescription process performs image analysis that is able to identify vertebrae and discs even in the presence of abnormalities. | 05-26-2011 |
20120020538 | Automated neuroaxis (brain and spine) imaging with iterative scan prescriptions, analysis, reconstructions, labeling, surface localization and guided intervention - Automated spine localizing, numbering and autoprescription system enhances correct location or diseased or injured tissue, even allow multi-spectral diagnosis. Externally located this tissue is facilitated by an integrated self adhesive spatial reference and skin marking system that is designed for a variety of modalities to include MRI, CT, SPECT, PET, planar nuclear imaging, radiography, XRT, thermography, optical imaging and 3D space tracking. The device ranges from a point localizer to a more multifunctional and complex grid/phantom system. The specially designed spatial reference(s) is affixed to an adhesive strip with corresponding markings so that after applying the unit to the skin/surface and imaging, the reference can be removed leaving the skin appropriately marked. The localizer itself can also directly adhere to the skin after being detached from the underlying strip. A spine autoprescription process performs image analysis that is able to identify vertebrae and discs even in the presence of abnormalities. | 01-26-2012 |
Patent application number | Description | Published |
20110077196 | NON-STANDARD INSULIN ANALOGUES - An insulin analogue comprises a B-chain polypeptide containing at least one alteration selected from a methylated phenylalanine substitution at position B24 and an addition of two amino acids to the carboxyl end of the B-chain polypeptide. A first amino acid at position B31 is selected from glutamate and aspartate, and a second amino acid at position B32 is selected from glutamate, alanine and aspartate. The methylated phenylalanine may be ortho-monofluoro-phenylalanine, meta-monobromo-phenylalanine or para-monochloro-phenylalanine. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. | 03-31-2011 |
20140303076 | NON-STANDARD INSULIN ANALOGUES - An insulin analogue comprises a B-chain polypeptide containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. A proinsulin analogue or single-chain insulin analogue containing a B domain containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. A method of semi-synthesis using an unprotected octapeptide by means of modification of an endogenous tryptic site by non-standard amino-acid substitutions. | 10-09-2014 |
20140323398 | ULTRA-CONCENTRATED RAPID-ACTING INSULIN ANALOGUE FORMULATIONS - A pharmaceutical formulation comprises insulin having a variant insulin B-chain polypeptide containing an ortho-monofluoro-Phenylalanine substitution at position B24 in combination with a substitution of an amino acid containing an acidic side chain at position B10, allowing the insulin to be present at a concentration of between 0.6 mM and 3.0 mM. The formulation may optionally be devoid of zinc. Amino-acid substitutions at one or more of positions B3, B28, and B29 may additionally be present. The variant B-chain polypeptide may be a portion of a proinsulin analogue or single-chain insulin analogue. The insulin analogue may be an analogue of a mammalian insulin, such as human insulin. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to the patient. | 10-30-2014 |
20150299286 | GLUTAMIC ACID-STABILIZED INSULIN ANALOGUES - An insulin analogue comprises a B-chain polypeptide containing the acidic two-residue extension GluB31-GluB32, and optionally an A-chain polypeptide containing acidic substitution GluA8, and additionally optionally a non-standard modification of PheB24. The analogue may also contain additional B-chain substitutions known in the art to enhance the rate of absorption of an insulin analogue formulation following subcutaneous injection or infusion. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. The analogue may be administered at a high concentration while maintaining fast-acting properties. A method of semi-synthesis using an unprotected octapeptide by means of modification of an endogenous tryptic site by non-standard amino-acid substitutions. | 10-22-2015 |